Hematologic Cancers

AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”

By

Tori Rodriguez, MA, LPC, AHC

Publish Date February 3, 2023

AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.

Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma

By

Leah Lawrence

Publish Date February 2, 2023

Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.

Charlson-Deyo Comorbidity Index Independent Predictor of Survival in Acute Promyelocytic Leukemia

By

Vicki Moore, PhD

Publish Date January 30, 2023

Researchers sought to show an association between Charlson-Deyo Comorbidity Index and survival outcomes.

Early Active Treatment Strategies Improve Outcomes in Newly Diagnosed High-Risk Myelodysplastic Syndrome

By

Vicki Moore, PhD

Publish Date January 27, 2023

Researchers sought to determine whether early treatment strategies would be beneficial in patients with newly diagnosed, high-risk MDS.

Tecartus Approved for Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

By

Brian Park, PharmD

Publish Date January 27, 2023

The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.